secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001683168-26-000217
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%
--------------------------------------------------------------------------------

- Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.
- 12-month survival doubled: 44.4% vs 22.3%; 24-month survival fivefold: 12.9% vs 2.6%.
- Safety profile consistent; serious TEAE 56.1% vs 56.4%; death-related TEAE 12.3% vs 16.7%.
- Biomarker data suggest potential predictive value for KRAS, ARID1A; increased CD8+ and NK cells in combination arm.
- Seventeen patients remain alive in elraglusib arm (3 >24 mo); none on GnP alone as of Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/0001683168-26-000217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-000217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer